Skip to main content

Advertisement

Table 1 Patient demographics and baseline characteristics

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

  GA to fingolimod Remaining on GA IM IFN beta-1a to fingolimod Remaining on IM IFN beta-1a SC IFN beta-1a to fingolimod Remaining on SC IFN beta-1a IFN beta-1b to fingolimod Remaining on IFN beta-1b
(n = 262) (n = 74) (n = 205) (n = 48) (n = 196) (n = 58) (n = 125) (n = 39)
Mean age (SD), years 46.3 (9.14) 44.4 (9.97) 46.6 (9.90) 45.1 (10.48) 45.0 (10.39) 45.9 (10.25) 46.3 (10.20) 47.5 (8.97)
Women, n (%) 208 (79.4) 61 (82.4) 160 (78.0) 38 (79.2) 137 (69.9) 44 (75.9) 94 (75.2) 33 (84.6)
Race, n (%)         
Caucasian 222 (84.7) 64 (86.5) 165 (80.5) 36 (75.0) 160 (81.6) 44 (75.9) 94 (75.2) 31 (79.5)
Black 24 (9.2) 9 (12.2) 35 (17.1) 10 (20.8) 29 (14.8) 14 (24.1) 24 (19.2) 6 (15.4)
Asian 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
Native American 2 (0.8) 0 (0.0) 0 (0.0) 1 (2.1) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other 12 (4.6) 1 (1.4) 5 (2.4) 1 (2.1) 5 (2.6) 0 (0.0) 6 (4.8) 2 (5.1)
Mean duration of MS symptoms (SD), years 13.1 (8.91) 12.2 (9.36) 12.0 (7.9) 11.5 (7.87) 11.1 (7.89) 11.4 (8.04) 12.2 (8.64) 12.3 (6.78)
Mean number of MS relapses (SD)         
Previous year 0.75 (5.53) 0.84 (3.12) 0.74 (5.54) 0.48 (1.66) 0.76 (6.30) 0.88 (3.64) 0.74 (3.90) 0.62 (1.84)
Previous 2 years 1.42 (9.60) 1.43 (5.81) 1.20 (7.78) 0.88 (2.72) 1.29 (8.54) 1.45 (5.05) 1.34 (5.50) 1.05 (2.83)
Mean EDSS score (SD) 2.5 (1.33) 2.4 (1.35) 2.5 (1.26) 2.4 (1.27) 2.4 (1.35) 2.3 (1.38) 2.4 (1.37) 2.5 (1.39)
  1. EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFN, interferon; IM, intramuscular; MS, multiple sclerosis; SC, subcutaneous; SD, standard deviation.